112 related articles for article (PubMed ID: 12227689)
1. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.
Sprague SM; Ho LT
Clin Nephrol; 2002 Aug; 58(2):155-60. PubMed ID: 12227689
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Coronel F; Rodríguez-Cubillo B; Cigarrán S; Gomis A
Adv Perit Dial; 2011; 27():130-3. PubMed ID: 22073844
[TBL] [Abstract][Full Text] [Related]
5. Doxercalciferol treatment of secondary hyperparathyroidism.
Dennis VC; Albertson GL
Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
[TBL] [Abstract][Full Text] [Related]
6. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
[TBL] [Abstract][Full Text] [Related]
7. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Zisman AL; Ghantous W; Schinleber P; Roberts L; Sprague SM
Am J Nephrol; 2005; 25(6):591-5. PubMed ID: 16282676
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
10. A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.
Mazess RB; Elangovan L
Clin Nephrol; 2003 May; 59(5):319-25. PubMed ID: 12779092
[TBL] [Abstract][Full Text] [Related]
11. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
12. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
[TBL] [Abstract][Full Text] [Related]
14. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
[TBL] [Abstract][Full Text] [Related]
15. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.
Upton RA; Knutson JC; Bishop CW; LeVan LW
Nephrol Dial Transplant; 2003 Apr; 18(4):750-8. PubMed ID: 12637645
[TBL] [Abstract][Full Text] [Related]
17. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
18. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
[No Abstract] [Full Text] [Related]
19. Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series.
Achinger SG; Mizani MR; Ayus JC
Hemodial Int; 2010 Apr; 14(2):193-9. PubMed ID: 20337743
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
